Johns Hopkins is once again in the top 10 among US universities: https://bit.ly/3VawSaP
10 || 2 Capital Partners, LLC
Investment Banking
Pittsburgh, Pennsylvania 287 followers
Driving Investment and Strategy for Transformational Companies and Niche Venture Capital Funds
About us
10 || 2 Capital Partners, LLC selectively drives bespoke capital raising, investor relations, and strategic partnerships for high-growth companies and niche venture capital funds focused on AI-based products and solutions within Life Sciences, Digital Health, Robotics, Medical Devices, Logistics, Supply Chain, SaaS, Industrials, Cybersecurity, and Cleantech. The investor base includes single-family offices, venture capital funds, endowments, foundations, corporations, sovereign wealth funds, and outsourced chief investment officer firms within North America, Europe, and the APAC region. Also effective at cross-functional collaboration, due diligence, strategy, writing, deal sourcing, group presentations, marketing materials, governance, analysis, and educating sophisticated investment committees, boards, syndicates, legal, and tax professionals. High-growth companies range from late-seed / Series A to lower middle-market businesses. Niche venture capital funds range from inaugural funds to fund V.
- Website
-
https://www.102capital.com
External link for 10 || 2 Capital Partners, LLC
- Industry
- Investment Banking
- Company size
- 2-10 employees
- Headquarters
- Pittsburgh, Pennsylvania
- Type
- Privately Held
- Founded
- 2016
- Specialties
- Capital Raising & Due Diligence, Investor Relations, AI, Life Sciences, Robotics, Automation, Medtech, Logistics & Supply Chain, Venture Capital, ML, Cross-Functional Team Leadership, Growth Capital, Entrepreneurship, and Strategic Partnerships
Locations
-
Primary
Get directions
Pittsburgh, Pennsylvania 15216, US
-
Get directions
747 3rd Ave
New York, NY 10017, US
-
Get directions
777 29th St
Boulder, Colorado 80303, US
Employees at 10 || 2 Capital Partners, LLC
Updates
-
I am grateful to be part of the mix... #biotechnology #mastersdegree #mbee #cuttingedgeresearch #positiveimpact #enterprise #lifesciences #raredisease #precisionmedicine #capital #cellandgenetherapy #topbiotechuniversitiesintheus #deriskinnovativetechnology #translationalscience #nextgenlifescience #aiinhealthcare #leadership #cns #strategy #businessdevelopment #commercialization
-
Early-stage biotech investment requires much more than financial engineering and providing introductions...glad to see the SMEs in VC are shining once again. #biotechinvestment #biotechinnovation #subjectmatterexperts #venturecapital #targetproductprofile #lifesciences #regulatoryrisks #translationalscience
Meet the 'biotech mafia': how specialized biotech VC firms are dominating industry funding once again
https://www.labiotech.eu
-
This pivotal ruling by the UK’s MHRA on CRISPR/Cas9 gene-edited therapy has the potential to revolutionize how sickle-cell disease and β-thalassaemia are treated. Stateside, the PDUFA date is Dec 8 this year and March 30, 2024 respectively... #Sicklecelldisease #betathalassemia #CRISPR #MHRA #genetherapy #vasoocclusivecrises #biotech #102capital #lifesciences
World’s first CRISPR medicine approved in UK for sickle cell, beta thalassemia
biopharmadive.com
-
More interesting news on a potential cell-based gene therapy product for Sickle Cell Disease resulting from the joint research program between Vertex and CRISPR Therapeutics... #sicklecelldisease #crisprcas9 #geneediting #genetherapy #biotech #fda #HSPCs #humangenome #raredisease #lifesciences #PDUFA #highunmetneeed
FDA Advisory Panel Finds Vertex's Off-Target Data Convincing for Approval
precisionmedicineonline.com
-
Some positive news for the biotech investment ecosystem in public and private markets... #biotech #healthcare #diagnostics #lifesciences #venturecapital #growthcapital #privatemarkets
OrbiMed raises $4.3B in new funds for startup investing
biopharmadive.com
-
An interesting report on how CGTs for orphan diseases and hematological cancers are 2x to 3.5x more likely to gain approval upon Phase 1 vs. other modalities #cellandgenetherapy #orphandiseases #bloodcancers #biotech #FDAapproval #drugdevelpment #102capital #lifesciences #privatemarkets
Orphan cell and gene therapies more likely to reach approval than larger drug pipeline: study
fiercebiotech.com
-
Some good points on the nuances of liquidation preferences during exits and fundraising rounds... #vc #m&a #ipo #liquidation #liquidationpreferences #earlystageinvestors #latestageinvestors #privatemarkets #valuation #capitalraising #downround
Liquidation preferences put collaborative VCs into conflict | PitchBook
pitchbook.com
-
A brief article underlying the main issues within AI-enabled drug discovery and disease treatment...once overcome, things will be quite interesting. #aiinhealthcare #drugdiscovery #lifesciences #ai #ml #deeplearning #diseasetreatment #biotech #102capital #medtech #computationalbiology
Using AI In Drug Discovery Isn't The Golden Solution You Think It Is — Yet.
drugdiscoveryonline.com
-
Another example of AI in healthcare that's lessening the administrative load placed on clinicians. An AI Co-Pilot will seemingly augment EMRs, allowing for more strides toward collaborative precision medicine. #aiinhealthcare #ai #healthcare #clinicianpatientinteraction #emr #precisionmedicine #medtech #ml #102capital #patientexperience
Corti, an AI 'co-pilot' for healthcare clinicians, raises $60M | TechCrunch
https://techcrunch.com